vTv Therapeutics Shares Soar in October, Near Term Catalysts, Analysts review and Target
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and diabetes as well as the treatment of inflammatory disorders.
Despite the lack of company news or announced catalyst, VTVT shares have jumped from $.78 per share to the current price of $3.45 thus far in October.
Analysts review, price target and potential near-term catalysts' READ MORE
Copy and paste to your browser may be required to view the report –https://tradersnewssource.com/vtv-therapeutics/
Since its recent announcement regarding the topline results from Part B of the STEADFAST Study, VTVT has continued to analyze the results from Parts A and B and are encouraged by its findings. Additionally, the company' other programs, including its glucokinase activator currently in clinical development for type 1 diabetes and its GLP-1R program that is being developed in partnership with Huadong Medicine for type 2 diabetes, continue to make steady progress.
Look at the company's pipeline progress and review the Q2 financial data READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/vtv-therapeutics/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
SOURCE: Traders News Source
